Canadian Respiratory Journal / 2017 / Article / Tab 4

Research Article

Galactomannan in Bronchoalveolar Lavage Fluid for Diagnosis of Invasive Pulmonary Aspergillosis with Nonneutropenic Patients

Table 4

Risk factors for false-positive galactomannan results in bronchoalveolar lavage assays with univariate analysis and logistic regression analysis, respectively.

VariablesCase patients
(), (%)
Control patients
(), (%)
Univariate analysisLogistic regression analysis

Age ≥ 60 years12 (40.0)51 (45.1)0.6150.533
Male gender13 (43.3)64 (56.6)0.1940.067
Seasonal distribution
 March–October23 (76.7)70 (61.9)0.1330.129
Underlying disease
 Emphysema2 (6.7)10 (8.8)0.9900.608
 COPD3 (10.0)5 (4.4)0.4630.121
 Bronchial asthma2 (6.7)5 (4.4)0.9760.273
 Pulmonary tuberculosis7 (23.3)10 (8.8)0.0630.117
 Solid tumor011 (9.7)0.1640.999
 Bronchiectasis7 (23.3)16 (14.2)0.3490.431
 Diabetes011 (9.7)0.1640.999
 Liver cirrhosis01 (0.9)1.0000.999
 Hematologic malignancy01 (0.9)1.0001.000
 Autoimmune disease02 (1.8)1.0000.999
 Kidney non-malignant disease1 (3.3)1 (0.9)0.3771.000
Antibiotics
 Piperacillin/tazobactam9 (30.0)22 (19.5)0.2130.479
 Mezlocillin/sulbactam2 (6.7)5 (4.4)0.9760.726
 Cephalosporins7 (23.3)49 (43.4)0.0460.157
 Quinolones7 (23.3)37 (32.7)0.3210.404

COPD, chronic obstructive pulmonary disease. Case patients are defined as individuals in the “non-invasive pulmonary aspergillosis (IPA)” group with positive bronchoalveolar lavage fluid (BALF) galactomannan (GM) results, excluding aspergilloma, ABPA, colonization, or contamination. Namely, the group is the other diagnosis with positive BALF GM results. Control patients are defined as individuals in the “non-IPA” group with negative BALF GM results, excluding aspergilloma, colonization, or contamination. Namely, the group is the other diagnosis with negative BALF GM results.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.